# Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)

> **NCT00362583** · PHASE3 · COMPLETED · sponsor: **Nycomed** · enrollment: 100 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Fentanyl

## Key facts

- **NCT ID:** NCT00362583
- **Lead sponsor:** Nycomed
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-10
- **Final completion:** 2008-03
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2012-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00362583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00362583, "Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00362583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*